

CHOLESTEROL

CHOD-PAP


Intended use:

Enzymatic in vitro test for the quantitative determination of cholesterol in human serum and plasma.

Summary:

Cholesterol is a steroid with a secondary hydroxyl group in the C₃ position. It is synthesized in many types of tissue, but particularly in the liver and intestinal wall. Approximately three quarters of cholesterol is newly synthesized and a quarter originates from dietary intake. Cholesterol assays are used for screening for atherosclerotic risk and in the diagnosis and treatment of disorders involving elevated cholesterol levels as well as lipid and lipoprotein metabolic disorders. Cholesterol analysis was first reported by Liebermann in 1885 followed by Burchard in 1889. In the Liebermann-Burchard reaction, cholesterol forms a blue-green dye from polymeric unsaturated carbohydrates in an acetic acid/acetic anhydride/ concentrated sulfuric acid medium. The Abell and Kendall method is specific for cholesterol, but is technically complex and requires the use of corrosive reagents. In 1974, Roeschlau and Allain described the first fully enzymatic method. This method is based on the determination of A⁴ cholestenone after enzymatic cleavage of the cholesterol ester by cholesterol esterase, conversion of cholesterol by cholesterol oxidase and subsequent measurement by the Trinder reaction of the hydrogen peroxide formed. Optimization of ester cleavage (>99.5%) allows standardization using primary and secondary standards and a direct comparison with the CDC and NIST reference methods. The Analyticon cholesterol assay meets the 1992 National Institutes of Health (NIH) goal of less than or equal to 3% for both precision and bias.

Test principle:



Cholesterol is converted by oxygen with the aid of cholesterol oxidase to A⁴-Cholestenone and hydrogen peroxide. Hydrogen peroxide created forms a red dyestuff by reacting with 4-aminoantipyrine and phenol under the catalytic action of peroxidase. The color intensity is directly proportional to the concentration of cholesterol and can be determined photometrically.

Reagent concentration:

| | |
|-----------------------------|------------|
| R1: | |
| Pipes buffer, pH 6.9 Phenol | 90 mmol/l |
| Cholesterol oxidase | 26 mmol/l |
| Cholesterol esterase | 200 U/l |
| Peroxidase | 1250 U/l |
| 4-Aminoantipyrine | 0,4 mmol/l |

Preparation and stability:

Reagent and standard are ready for use.
The unopened kit components: Up to expiry date at +2°C to +8°C
Onboard stability: R1: 28 days

Specimen:

Collect serum using standard sampling tubes.
Heparinized or EDTA plasma. Do not use citrate, oxalate or fluoride-plasma. Stability: 5 - 7 days at +2°C to +8°C
3 months at -20°C
Fasting and nonfasting samples can be used.

Limitations - interference:

Criterion: Recovery within ±10% of initial value.

Icterus: No significant interference up to an index I of 8 (approximate bilirubin concentration: 8 mg/dl).
Hemolysis: No significant interference up to an index H of 450 (approximate hemoglobin concentration: 450 mg/dl).

Testing procedure:

Applications for automated systems are available on request.

Materials provided

- Working solutions as described above *Additional materials required*
- Calibrators and controls as indicated below
- 0.9% NaCl

| | | |
|--|-----------------|---------------------|
| Manual procedure | | |
| Wavelength: | 540 nm | |
| Temperature: | +37°C | |
| Cuvette: | 1 cm light path | |
| Zero adjustment: | Reagent blank | |
| | Blank | Sample / Calibrator |
| Sample / Calibrator | - | 10 µl |
| R1 | 1000 µl | 1000 µl |
| Mix and incubate 5 minutes. Read the absorbance against blank within 30 minutes. | | |
| <u>Calculation:</u> | | |
| AA sample x Calibrator conc. = Cholesterol in mg/dl | | |
| AA Calibrator | | |

Measuring/reportable range:

30-800 mg/dl
Determine samples having higher activities via the rerun function. On instruments without rerun function, manually dilute the samples with 0.9% NaCl-solution or distilled/deionized water (e.g. 1 + 2). Multiply the result by the appropriate dilution factor (e.g. factor 3).

Expected values:

| | | |
|---|-----------------|---------------------------------------|
| Clinical Interpretation according to the recommendations of the European atherosclerosis Society. | | |
| Cholesterol Triglycerides | below 200 mg/dl | No |
| Cholesterol | 200 - 300 mg/dl | yes if HDL-Cholesterol below 33 mg/dl |
| Cholesterol Triglycerides | above 300 mg/dl | Yes |

Recommendations of the NCEP Adult Treatment Panel for the following risk-cut-off thresholds for the US American population
Desirable cholesterol level: <200 mg/dl
Borderline high cholesterol: 200-239 mg/dl
High cholesterol: >240 mg/dl

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference range. For diagnostic purposes the cholesterol results should always be assayed in conjunction with the patient's medical history, clinical examinations and other findings. At least two measurements of cholesterol on separate occasions should be made before any medical decision is made, since a single point total cholesterol measurement may not represent a patient's usual cholesterol concentration.

Analytical sensitivity (lower detection limit)

Detection limit: 30 mg/dl
The lower detection limit represents the lowest measurable cholesterol concentration that can be distinguished from zero.

Method comparison:

A comparison of the BIOANALYTIC CHOL (y) with a commercial obtainable assay (x) gave following result: y = 1.006 x + 0.258; r = 0.999

Quality Control:

| | |
|----------------|-------------------|
| Control Serum: | |
| BIOCON N | 5 x 5 ml # B10814 |
| BIOCON P | 5 x 5 ml # B10817 |

The control intervals and limits must be adapted to the individual laboratory and country-specific requirements. Values obtained should fall within established limits. Each laboratory should establish corrective measures to be taken if values fall outside the limits.

Calibration:

| | |
|---------------|-------------------|
| S1: 0.9% NaCl | |
| S2: BIOCAL H | 5 x 3 ml # B11895 |



CHOLESTEROL

CHOD-PAP

Calibration frequency:

A two-point-calibration is recommended in case of:

- 1-change of lot
- 2- quality control requirements

Imprecision:

Reproducibility was determined using controls. The following results were obtained:

| Sample | Between day | | |
|-----------------|-------------|----------|------|
| | Mean mg/dl | SD mg/dl | % CV |
| Control serum 1 | 124 | 1.71 | 1.38 |
| Control serum 2 | 162 | 3.13 | 1.93 |
| Control serum 3 | 186 | 1.97 | 1.06 |

Literature:

1. Abell L. et al. Standard Methods in Clinical Chemistry 1958; 26:2.
2. Allain C.C. et al. Clin Chem 1974;20:470
3. Burchard H. Beiträge zur Kenntnis der Cholesterine. Dissertation Rostock 1889.
4. Cohn J.S., McNamara J.R., Schaefer E.J.. Lipoprotein Cholesterol Concentrations in the plasma of Human Subjects as Measured in the fed and Fasted States. Clin. Chem 1988;34:2456-2459
5. Glick M.R., Ryder K.W., Jackson SA.. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-474
6. Greinling H., Gressner A.M. eds. Lehrbuch der Klinischen Chemie und Pathobiochemie. 3rd ed. Stuttgart/New York: Schattauer, 1995
7. Liebermann C. Ber Dtsch chem Ges 1885; 18:1803
8. Pisani T., Gebiski C.P., Leary E.T. et al. Accurate Direct Determination of Low-density Lipoprotein Cholesterol Using an Immunoseparation Reagent and Enzymatic Cholesterol Assay. Arch. Pathol Lab Med 1995;119:1127
9. Recommendations for Improving Cholesterol Measurement: A Report from the Laboratory Standardization Panel of the National Cholesterol Education Program. NIH Publication No. 90-2964, February 1990
10. Roeschlau P. et al. Z Klein Chem Klein Biochem 1974;12:226
11. Second Report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. NIH Publikation No. 93-3096, September 1993
12. Siedel J. Hagele E.O., Ziegenhorn J. et al. Clin Chem 1983;29:1075.
13. Study Group, European Atherosclerosis Society. Strategies for the prevention of coronary heart disease: A policy statement of the European Atherosclerosis Society. European Heart Journal 1987;8:77
14. Thomas, L., Labor und Diagnose, 5th. ed. (1998)
15. Tietz N.W. eds. Clinical Guide to Laboratory Tests, 3.Auflage.Philadelphia, Pa: W.B. Saunders Company, 1995:130-131
- Wiebe D.A., Bernert J.T. Clin Chem. 1984;30:35





Order information (Cat No.):

| | | | | | |
|----------|----------|--------|--------|--------|--------|
| CC380 | AB380 | B25080 | B30080 | B33081 | B37081 |
| SH380 | BCHOL250 | B25081 | B30081 | B34080 | B42080 |
| CR380 | B21080 | B27080 | B31080 | B35080 | B80080 |
| OL380 | B21081 | B27081 | B32080 | B36080 | B80081 |
| KL380 | B22080 | B28080 | B32081 | B36081 | B80082 |
| BCHOL500 | B24080 | B28081 | B33080 | B37080 | |

Manufacturer

Diaclinica Diagnostik Kimya.San.Tic.Ltd.Şti
Adress : İkitelli O.S.B Mutsan San.Sit. M4 Blok No:17-19 Başakşehir/İSTANBUL
Tel:+90(212) 549 33 88- Fax:+90 (212) 549 55 50
Web :www.diaclinica.com

SYMBOLS

- IVD** for in vitro diagnostic use only
- LOT** lot of manufacturing
- REF** code number
-  storage at temperature interval
-  expiration date (year/month)
-  warning, read enclosed documents
-  Read the directions



ISO 9001:2015
ISO 13485:2016

